Nkarta Inc NKTX

NAS: NKTX | ISIN: US65487U1088   14/11/2024
2,700 USD (-7,22%)
(-7,22%)   14/11/2024

Nkarta Announces February and March 2021 Investor Conference Schedule

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:

SVB Leerink 10th Annual Global Healthcare Conference
February 26, 2021
Fireside chat presentation: 1:40 p.m. ET

Cowen 41st Annual Health Care Conference
March 3-4, 2021
No presentation

Barclays Global Healthcare Conference
March 11, 2021
Fireside chat presentation: 10:20 a.m. ET

Live audio webcasts of the presentations will be available on the Investors section of Nkarta’s website, www.nkartatx.com. Replays of the webcasts will be archived on the website for approximately four weeks.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, which are engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com


Mijn selecties